Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α

Gastroenterology

Volumn 128, Issue 2, 2005, Pages 376-392

  Mitoma, Hiroki ^a   Horiuchi, Takahiko ^a   Hatta, Nobuaki ^b   Tsukamoto, Hiroshi ^a   Harashima, Shin Ichi ^a   Kikuchi, Yuji ^a   Otsuka, Junji ^a   Okamura, Seiichi ^c   Fujita, Shigeru ^b   Harada, Mine ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b EHIME UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALANINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CASPASE 3; CASPASE 8; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOHEXIMIDE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 10; PROTEIN BAK; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; RITUXIMAB; SERINE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; HYBRID PROTEIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PRIMER DNA; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

AMINO ACID SUBSTITUTION; ANALYTIC METHOD; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOPLASM; DRUG POTENCY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE; BIOSYNTHESIS; CELL DIVISION; CELL MEMBRANE; CROHN DISEASE; DRUG EFFECT; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; SITE DIRECTED MUTAGENESIS;

AMINO ACID SUBSTITUTION; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BASE SEQUENCE; CELL CYCLE; CELL DIVISION; CELL MEMBRANE; CROHN DISEASE; DNA PRIMERS; E-SELECTIN; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-10; JURKAT CELLS; MUTAGENESIS, SITE-DIRECTED; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SERINE; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 14944382276     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2004.11.060     Document Type: Article

References (50)

1. R.A. Black, C.T. Rauch, C.J. Kozlosky, J.J. Peschon, J.L. Slack, M.F. Wolfson, B.J. Castner, K.L. Stocking, P. Reddy, S. Srinivasan, N. Nelson, N. Boiani, K.A. Schooley, M. Gerhart, R. Davis, J.N. Fitzner, R.S. Johnson, R.J. Paxton, C.J. March, D.P. Cerretti A metalloproteinase disintegrin that releases tumour necrosis factor-α from cells Nature 385 1997 729 733
2. M.L. Moss, S.L. Jin, M.E. Milla, D.M. Bickett, W. Burkhart, H.L. Carter, W.J. Chen, W.C. Clay, J.R. Didsbury, D. Hassler, C.R. Hoffman, T.A. Kost, M.H. Lambert, M.A. Leesnitzer, P. McCauley, G. McGeehan, J. Mitchell, M. Moyer, G. Pahel, W. Rocque, L.K. Overton, F. Schoenen, T. Seaton, J.L. Su, J.D. Becherer Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha Nature 385 1997 733 736
3. L.J. Old Tumor necrosis factor (TNF) Science 230 1985 630 632
4. P. Vassalli The pathophysiology of tumor necrosis factors Annu Rev Immunol 10 1992 411 452
5. P. Vandenabeele, W. Declercq, R. Beyaert, W. Fiers Two tumour necrosis factor receptors structure and function Trends Cell Biol 5 1995 392 399
6. G. Caron, Y. Delneste, J.P. Aubry, G. Magistrelli, N. Herbault, A. Blaecke, A. Meager, J.Y. Bonnefoy, P. Jeannin Human NK cells constitutively express membrane TNF-α (mTNF-α) and present mTNF-α-dependent cytotoxic activity Eur J Immunol 29 1999 3588 3595
7. T. Decker, M.L. Lohmann-Matthes, G.E. Gifford Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages J Immunol 138 1987 957 962
8. S.L. Parry, M. Sebbag, M. Feldmann, F.M. Brennan Contact with T cells modulates monocyte IL-10 production role of T cell membrane TNF-α J Immunol 158 1997 3673 3681
9. M. Kriegler, C. Perez, K. DeFay, I. Albert, S.D. Lu A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein ramifications for the complex physiology of TNF Cell 53 1988 45 53
10. D. Macchia, F. Almerigogna, P. Parronchi, A. Ravina, E. Maggi, S. Romagnani Membrane tumour necrosis factor-α is involved in the polyclonal B-cell activation induced by HIV-infected human T cells Nature 363 1993 464 466
11. M. Higuchi, K. Nagasawa, T. Horiuchi, M. Oike, Y. Ito, M. Yasukawa, Y. Niho Membrane tumor necrosis factor-α (TNF-α) expressed on HTLV-I-infected T cells mediates a costimulatory signal for B cell activation--characterization of membrane TNF-α Clin Immunol Immunopathol 82 1997 133 140
12. M. Grell, E. Douni, H. Wajant, M. Lohden, M. Clauss, B. Maxeiner, S. Georgopoulos, W. Lesslauer, G. Kollias, K. Pfizenmaier The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor Cell 83 1995 793 802
13. J. Lou, J.M. Dayer, G.E. Grau, D. Burger Direct cell/cell contact with stimulated T lymphocytes induces the expression of cell adhesion molecules and cytokines by human brain microvascular endothelial cells Eur J Immunol 26 1996 3107 3113
14. G. Aversa, J. Punnonen, J.E. de Vries The 26-kD transmembrane form of tumor necrosis factor α on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation J Exp Med 177 1993 1575 1585
15. A.D. Watts, N.H. Hunt, Y. Wanigasekara, G. Bloomfield, D. Wallach, B.D. Roufogalis, G. Chaudhri A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in "reverse signalling." EMBO J 18 1999 2119 2126
16. S. Harashima, T. Horiuchi, N. Hatta, C. Morita, M. Higuchi, T. Sawabe, H. Tsukamoto, T. Tahira, K. Hayashi, S. Fujita, Y. Niho Outside-to-inside signal through the membrane TNF-α induces E-selectin (CD62E) expression on activated human CD4+ T cells J Immunol 166 2001 130 136
17. B. Lohrengel, M. Lu, M. Roggendorf Molecular cloning of the woodchuck cytokines TNF-α, IFN-γ, and IL-6 Immunogenetics 47 1998 332 335
18. E. Pocsik, E. Duda, D. Wallach Phosphorylation of the 26 kDa TNF precursor in monocytic cells and in transfected HeLa cells J Inflamm 45 1995 152 160
19. J.M. Bathon, R.W. Martin, R.M. Fleischmann, J.R. Tesser, M.H. Schiff, E.C. Keystone, M.C. Genovese, M.C. Wasko, L.W. Moreland, A.L. Weaver, J. Markenson, B.K. Finck A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N Engl J Med 343 2000 1586 1593
20. P.E. Lipsky, D.M. van der Heijde, E.W. St. Clair, D.E. Furst, F.C. Breedveld, J.R. Kalden, J.S. Smolen, M. Weisman, P. Emery, M. Feldmann, G.R. Harriman, R.N. Maini Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group N Engl J Med 343 2000 1594 1602
21. S.R. Targan, S.B. Hanauer, S.J. van Deventer, L. Mayer, D.H. Present, T. Braakman, K.L. DeWoody, T.F. Schaible, P.J. Rutgeerts A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group N Engl J Med 337 1997 1029 1035
22. P.J. Mease, B.S. Goffe, J. Metz, A. VanderStoep, B. Finck, D.J. Burge Etanercept in the treatment of psoriatic arthritis and psoriasis a randomised trial Lancet 356 2000 385 390
23. J.D. Gorman, K.E. Sack, J.C. Davis Jr Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α N Engl J Med 346 2002 1349 1356
24. J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten, W. Golder, E. Gromnica-Ihle, H. Kellner, A. Krause, M. Schneider, H. Sorensen, H. Zeidler, W. Thriene, J. Sieper Treatment of active ankylosing spondylitis with infliximab a randomised controlled multicentre trial Lancet 359 2002 1187 1193
25. S. Munoz-Fernandez, V. Hidalgo, J. Fernandez-Melon, A. Schlincker, E. Martin-Mola Effect of infliximab on threatening panuveitis in Behçet's disease Lancet 358 2001 1644
26. D.M. Knight, H. Trinh, J. Le, S. Siegel, D. Shealy, M. McDonough, B. Scallon, M.A. Moore, J. Vilcek, P. Daddona Construction and initial characterization of a mouse-human chimeric anti-TNF antibody Mol Immunol 30 1993 1443 1453
27. K.M. Mohler, D.S. Torrance, C.A. Smith, R.G. Goodwin, K.E. Stremler, V.P. Fung, H. Madani, M.B. Widmer Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists J Immunol 151 1993 1548 1561
28. H. Mitoma, T. Horiuchi, H. Tsukamoto Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-α Gastroenterology 126 2004 934 935
29. W.J. Sandborn, S.B. Hanauer, S. Katz, M. Safdi, D.G. Wolf, R.D. Baerg, W.J. Tremaine, T. Johnson, N.N. Diehl, A.R. Zinsmeister Etanercept for active Crohn's disease a randomized, double-blind, placebo-controlled trial Gastroenterology 121 2001 1088 1094
30. D. Himeji, T. Horiuchi, H. Tsukamoto, K. Hayashi, T. Watanabe, M. Harada Characterization of caspase-8L a novel isoform of caspase-8 that behaves as an inhibitor of the caspase cascade Blood 99 2002 4070 4078
31. J.M. Van den Brande, H. Braat, G.R. van den Brink, H.H. Versteeg, C.A. Bauer, I. Hoedemaeker, C. van Montfrans, D.W. Hommes, M.P. Peppelenbosch, S.J. van Deventer Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease Gastroenterology 124 2003 1774 1785
32. A. Lugering, M. Schmidt, N. Lugering, H.G. Pauels, W. Domschke, T. Kucharzik Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway Gastroenterology 121 2001 1145 1157
33. T. Miyashita, J.C. Reed Tumor suppressor p53 is a direct transcriptional activator of the human bax gene Cell 80 1995 293 299
34. K. Kannan, N. Amariglio, G. Rechavi, J. Jakob-Hirsch, I. Kela, N. Kaminski, G. Getz, E. Domany, D. Givol DNA microarrays identification of primary and secondary target genes regulated by p53 Oncogene 20 2001 2225 2234
35. W.S. el-Deiry, T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, B. Vogelstein WAF1, a potential mediator of p53 tumor suppression Cell 75 1993 817 825
36. F. Cornillie, D. Shealy, G. D'Haens, K. Geboes, G. Van Assche, J. Ceuppens, C. Wagner, T. Schaible, S.E. Plevy, S.R. Targan, P. Rutgeerts Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease Aliment Pharmacol Ther 15 2001 463 473
37. B. Scallon, A. Cai, N. Solowski, A. Rosenberg, X.Y. Song, D. Shealy, C. Wagner Binding and functional comparisons of two types of tumor necrosis factor antagonists J Pharmacol Exp Ther 301 2002 418 426
38. R. Kuhn, J. Lohler, D. Rennick, K. Rajewsky, W. Muller Interleukin-10-deficient mice develop chronic enterocolitis Cell 75 1993 263 274
39. A. Tagore, W.M. Gonsalkorale, V. Pravica, A.H. Hajeer, R. McMahon, P.J. Whorwell, P.J. Sinnott, I.V. Hutchinson Interleukin-10 (IL-10) genotypes in inflammatory bowel disease Tissue Antigens 54 1999 386 390
40. R.N. Fedorak, A. Gangl, C.O. Elson, P. Rutgeerts, S. Schreiber, G. Wild, S.B. Hanauer, A. Kilian, M. Cohard, A. LeBeaut, B. Feagan Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group Gastroenterology 119 2000 1473 1482
41. S. Schreiber, R.N. Fedorak, O.H. Nielsen, G. Wild, C.N. Williams, S. Nikolaus, M. Jacyna, B.A. Lashner, A. Gangl, P. Rutgeerts, K. Isaacs, S.J. van Deventer, J.C. Koningsberger, M. Cohard, A. LeBeaut, S.B. Hanauer Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group Gastroenterology 119 2000 1461 1472
42. D. van Essen, H. Kikutani, D. Gray CD40 ligand-transduced co-stimulation of T cells in the development of helper function Nature 378 1995 620 623
43. S.R. Wiley, R.G. Goodwin, C.A. Smith Reverse signaling via CD30 ligand J Immunol 157 1996 3635 3639
44. I. Suzuki, P.J. Fink The dual functions of fas ligand in the regulation of peripheral CD8+ and CD4+ T cells Proc Natl Acad Sci U S A 97 2000 1707 1712
45. J. Lotem, M. Peled-Kamar, Y. Groner, L. Sachs Cellular oxidative stress and the control of apoptosis by wild-type p53, cytotoxic compounds, and cytokines Proc Natl Acad Sci U S A 93 1996 9166 9171
46. T.M. Johnson, Z.X. Yu, V.J. Ferrans, R.A. Lowenstein, T. Finkel Reactive oxygen species are downstream mediators of p53-dependent apoptosis Proc Natl Acad Sci U S A 93 1996 11848 11852
47. Y.T. Ip, R.J. Davis Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development Curr Opin Cell Biol 10 1998 205 219
48. T. Buschmann, O. Potapova, A. Bar-Shira, V.N. Ivanov, S.Y. Fuchs, S. Henderson, V.A. Fried, T. Minamoto, D. Alarcon-Vargas, M.R. Pincus, W.A. Gaarde, N.J. Holbrook, Y. Shiloh, Z. Ronai Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress Mol Cell Biol 21 2001 2743 2754
49. H. Grassme, J. Bock, J. Kun, E. Gulbins Clustering of CD40 ligand is required to form a functional contact with CD40 J Biol Chem 277 2002 30289 30299
50. Y. Nonomura, H. Kohsaka, K. Nagasaka, N. Miyasaka Gene transfer of a cell cycle modulator exerts anti-inflammatory effects in the treatment of arthritis J Immunol 171 2003 4913 4919